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TABLE 1 Change in Lipid and Lipoproteins and Atheroma Progression
Tertile 1 Tertile 2 Tertile 3 p Value
p Value Adjusting
for Treatment Group
LDL-C 0.44  0.24 0.14  0.24 0.32  0.24 0.71 0.69
HDL-C 0.64  0.24 0.43  0.24 –0.22  0.24 0.01 0.10
Triglyceride –0.03  0.24 0.35  0.24 0.59  0.24 0.07 0.19
Total LDL particles 0.04  0.24 0.35  0.24 0.39  0.24 0.32 0.97
Mean LDL
particle size
0.82  0.24 0.51  0.24 –0.54  0.24 <0.001 0.003
Large LDL 0.65  0.24 0.16  0.24 –0.04  0.24 0.047 0.25
Small LDL –0.35  0.24 0.44  0.24 0.70  0.24 0.002 0.07
Values are mean  SD. Changes in percent atheroma volume were stratiﬁed according to tertiles of percentage change in lipid and lipoprotein parameters.
C ¼ cholesterol; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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329not surprising because of the established cardiovas-
cular risk in this setting.
Insulin resistance, hyperglycemia, hypertrigly-
ceridemia, and systemic inﬂammation promote small
LDL particle accumulation in diabetes. Even after
controlling for the favorable effects of pioglitazone
on these factors, increasing LDL particle size was
associated with less disease progression. This has
important implications for the development of
diabetic therapies and the increased use of lipid-
lowering agents to more effectively lower cardiovas-
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Interpreting
Blood Pressure in
Younger Adults
The remarkable paper from the Chicago Heart Asso-
ciation Detection Project in Industry Study (1) studied
cardiovascular mortality (3,119 deaths) over 31 years
in 27,081 initially well persons, according to initial
categorizations of systolic and diastolic hypertension,
isolated diastolic hypertension, isolated systolic
hypertension (ISH), high-normal blood pressure (BP),
and optimal-normal BP. The results validate recent
concerns that results of treating elderly persons
(>60 years) cannot be applied universally to younger
persons, as in the 18- to 49-year age group described
here (2).
The Central Illustration in Yano et al. (1) shows,
for male subjects, little or no deviation in outcome
up to 20 years compared with high-normal BP or
optimal-normal BP, but considerable deviation from
the other 2 hypertensive groups. We have argued
that ISH in young male subjects may be “spurious”
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330(3) if based solely on the brachial cuff measure-
ment of systolic pressure without taking into ac-
count the shape of the pressure waveform in
central and peripheral (i.e., brachial and/ or radial)
arteries. We have pressed this view (4) on the
European Society of Hypertension/European Society
of Cardiology committee (Yano et al. [1] reference
6) on the basis that elevated brachial and radial
systolic pressure in young persons (especially tall
male subjects) is caused by an exaggerated narrow
systolic pressure peak of the radial and brachial
pressure waves but a normal aortic pulse. This
contrasts with elevated systolic pressure (i.e., ISH)
in persons over age 60 years who almost invariably
have a much broader systolic peak, which is similar
in the aorta and upper limb arteries (Yano et al. [1]
reference 41).
On the basis of outcomes in the Chicago study,
one would ﬁnd it hard to justify a randomized study
of therapy compared with placebo in ISH of adult
male subjects <50 years of age. Another important
factor in guidelines, addressed by a cardiology
fellow in the same issue of the journal (5) is “patient
preference.” For the trivial difference in outcome at
20 years, would not most male subjects wish to defer
the stigma of disease, the expense, the inconve-
nience, and side effects of treatment for another
year or 2 until issues are clariﬁed? How are young
fellows (5) expected to include opinions, guidelines,
and patient preference in their discussions with
patients <50 years of age with ISH?*Michael F. O’Rourke, MD DSc
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REPLY: Interpreting Blood Pressure inYoung AdultsWe thank Dr. O’Rourke and colleagues for their in-
terest in our ﬁndings. Their comments are primarily
focused on how our ﬁndings can be translated into
practice or policy. We urge caution when extrapo-
lating epidemiological ﬁndings to clinical recom-
mendations. Research ﬁndings, especially those from
observational studies, need to be interpreted within
the context of global evidence. Unfortunately, evi-
dence is sparse pertaining to long-term outcomes in
younger adults with isolated systolic hypertension
(ISH). Considering the limited prognostic data on ISH
at younger ages, which our data begin to address, we
agree with the comment that it would be premature
and difﬁcult to conduct randomized intervention
trials in a population of younger individuals who
would be at low risk for events in the near term. We
suggest that the next major step is to replicate our
results in other studies with long-term follow-up of
younger adults (1,2).
The letter also addresses precision (personalized)
medicine. Execution of precision medicine in younger
adultswith ISHwill (partly) resolve concerns regarding
patient preference, unnecessary expense, and adverse
effects associated with treatments (3). ISH in younger
adults appears to be a heterogeneous condition; some
have higher stroke volume, whereas others have
higher aortic stiffness, or both (4). One size does not
seem to ﬁt all in the clinical management of ISH at
younger ages. The optimal means to identify higher-
risk groups among younger ISH patients merits
further research. Clinical characteristics (e.g., body
weight, diabetes), biomarkers (e.g., brain natriuretic
peptide), and out-of-ofﬁce blood pressure measure-
ment (e.g., home or ambulatorymonitoring) may serve
to identify higher-risk individuals. Rather than treat-
ing ISH in younger adults as a monolithic disease
and continuing to debate whether it is “pseudo” or
“spurious” hypertension, detailed phenotyping of
ISH patients based on (patho) physiology and global
context of risk for cardiovascular eventswould seem to
be most useful to assess an individual patient’s ex-
pected net beneﬁt from therapy.Yuichiro Yano, MD, PhD
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